|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02181 MABPHARM-B
Nominal 
0.450 -0.025 (-5.263%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 397,941 | 45.137% | 646,095 | 258,228 | 87,161 | 55,918 |
| Cost of Sales | (36,385) | 10.465% | (72,444) | (38,834) | (11,923) | (15,375) |
| Gross Profit | 361,556 | 49.871% | 573,651 | 219,394 | 75,238 | 40,543 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (2,150) | -- | (125) | (1,879) | (427) | (118) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 31,360 | 982.126% | 4,160 | (127,947) | (209,356) | (210,819) | |
| Taxation | 0 | -- | 52,973 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 31,360 | 982.126% | 57,133 | (127,947) | (209,356) | (210,819) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 5,108 | -1.390% | 10,376 | 10,039 | 9,427 | 6,806 |
| Depreciation & Amortisation | 29,968 | 0.147% | 59,782 | 61,329 | 60,695 | 51,549 |
| Directors' Emoluments | -- | -- | -- | 15,497 | 11,447 | 7,878 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 1.000 | 1323.082% | 1.000 | -3.000 | -5.000 | -5.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.020 | (0.001) | 0.014 | (0.014) |
| NBV per share ($) | 0.047 | -- | 0.038 | 0.022 | 0.050 | 0.097 |
| Remarks: | Real time quote last updated: 10/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 31,360 |
| %Change | 982.126% |
| EPS / (LPS) | RMB 0.010 |
| NBV Per Share (¥) | RMB 0.047 |